Immunotherapy with the EGFR-speciWc mAb cetuximab is clinically eVective in 10-20% of patients with squamous cell carcinoma of the head and neck (SCCHN). Little information is available about the mechanism(s) underlying patients' diVerential clinical response to cetuximab-based immunotherapy, although this information may contribute to optimizing the design of cetuximab-based immunotherapy. Our understanding of these mechanisms would beneWt from the characterization of the variables which inXuence the extent of cell dependent-lysis of SCCHN cells incubated with cetuximab in vitro. Therefore, in this study we have investigated the role of Fc R IIIa-158 genotype expressed by eVector NK cells, cetuximab concentration, and EGFR expression level by SCCHN cells in the extent of their in vitro lysis and in the degree of NK cell activation. PBMC or puriWed CD56 + NK cells genotyped at IIIa codon 158 and SCCHN cell lines expressing diVerent levels of EGFR have been used as eVectors and targets, respectively, in antibody dependent cellular cytotoxicity (ADCC) assays. Furthermore, supernatants from ADCC assays were analyzed for cytokine and chemokine levels using multiplexed ELISA. We found that the extent of lysis of SCCHN cells was inXuenced by the EGFR expression level, cetuximab concentration, and Fc R polymorphism. EVector cells expressing the Fc R IIIa-158 VV allele were signiWcantly (P < 0.0001) more eVective than those expressing Fc R IIIa VF and FF alleles in mediating lysis of SCCHN cells expressed higher levels of the activation markers CD69 and CD107a, and secreted signiWcantly (P < 0.05) larger
Unfortunately a typo error has occurred in line 27 of the original abstract. The Wnal text should read "VF and FF" instead of "VF and VV".
The correct text is given below:
Abstract
Immunotherapy with the EGFR-speciWc mAb cetuximab is clinically eVective in 10-20% of patients with squamous cell carcinoma of the head and neck (SCCHN). Little information is available about the mechanism(s) underlying patients' diVerential clinical response to cetuximab-based immunotherapy, although this information may contribute to optimizing the design of cetuximab-based immunotherapy. Our understanding of these mechanisms would beneWt from the characterization of the variables which inXuence the extent of cell dependent-lysis of SCCHN cells incubated with cetuximab in vitro. Therefore, in this study we have investigated the role of Fc R IIIa-158 genotype expressed by eVector NK cells, cetuximab concentration, and EGFR expression level by SCCHN cells in the extent of their in vitro lysis and in the degree of NK cell activation. PBMC or puriWed CD56 + NK cells genotyped at IIIa codon 158 and SCCHN cell lines expressing diVerent levels of EGFR have been used as eVectors and targets, respectively, in antibody dependent cellular cytotoxicity (ADCC) assays. Furthermore, supernatants from ADCC assays were analyzed for cytokine and chemokine levels using multiplexed ELISA. We found that the extent of lysis of SCCHN cells was inXuenced by the EGFR expression level, cetuximab concentration, and Fc R polymorphism. EVector cells expressing the Fc R IIIa-158 VV allele were signiWcantly (P < 0.0001) more eVective than those expressing Fc R IIIa VF and FF alleles in mediating lysis of SCCHN cells expressed higher levels of the activation markers CD69 and CD107a, and secreted signiWcantly (P < 0.05) larger amounts of inXammatory cytokines and chemokines. 
